Avicanna Stock Current Valuation
| AVCN Stock | CAD 0.28 0.02 7.69% |
Valuation analysis of Avicanna helps investors to measure Avicanna's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 26th of November 2024, Enterprise Value is likely to grow to about 59.2 M, though Enterprise Value Over EBITDA is likely to grow to (4.00). Fundamental drivers impacting Avicanna's valuation include:
Price Book 837.7833 | Enterprise Value 29.6 M | Enterprise Value Ebitda (4.26) | Price Sales 1.1453 | Enterprise Value Revenue 1.1886 |
Overvalued
Today
Please note that Avicanna's price fluctuation is out of control at this time. Calculation of the real value of Avicanna is based on 3 months time horizon. Increasing Avicanna's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Avicanna is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avicanna Stock. However, Avicanna's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.28 | Real 0.25 | Hype 0.23 | Naive 0.25 |
The intrinsic value of Avicanna's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Avicanna's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Avicanna helps investors to forecast how Avicanna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avicanna more accurately as focusing exclusively on Avicanna's fundamentals will not take into account other important factors: Avicanna Company Current Valuation Analysis
Avicanna's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Avicanna Current Valuation | 29.57 M |
Most of Avicanna's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avicanna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avicanna Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Avicanna is extremely important. It helps to project a fair market value of Avicanna Stock properly, considering its historical fundamentals such as Current Valuation. Since Avicanna's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avicanna's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avicanna's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Avicanna has a Current Valuation of 29.57 M. This is 99.79% lower than that of the Pharmaceuticals sector and 99.6% lower than that of the Health Care industry. The current valuation for all Canada stocks is 99.82% higher than that of the company.
Avicanna Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avicanna's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avicanna could also be used in its relative valuation, which is a method of valuing Avicanna by comparing valuation metrics of similar companies.Avicanna is currently under evaluation in current valuation category among its peers.
Avicanna Current Valuation Drivers
We derive many important indicators used in calculating different scores of Avicanna from analyzing Avicanna's financial statements. These drivers represent accounts that assess Avicanna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avicanna's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 50.9M | 38.5M | 32.2M | 24.3M | 29.6M | 58.5M | |
| Enterprise Value | 51.8M | 39.2M | 33.8M | 26.3M | 31.0M | 59.2M |
Avicanna Fundamentals
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 29.57 M | ||||
| Shares Outstanding | 109.57 M | ||||
| Shares Owned By Insiders | 23.21 % | ||||
| Number Of Shares Shorted | 303.15 K | ||||
| Price To Book | 837.78 X | ||||
| Price To Sales | 1.15 X | ||||
| Revenue | 16.79 M | ||||
| Gross Profit | 1.12 M | ||||
| EBITDA | (6.9 M) | ||||
| Net Income | (7.89 M) | ||||
| Cash And Equivalents | 12.98 M | ||||
| Cash Per Share | 0.66 X | ||||
| Total Debt | 1.8 M | ||||
| Debt To Equity | 6.30 % | ||||
| Current Ratio | 4.31 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (1.4 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.10) X | ||||
| Target Price | 0.7 | ||||
| Number Of Employees | 87 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 27.94 M | ||||
| Total Asset | 21.97 M | ||||
| Retained Earnings | (98.71 M) | ||||
| Working Capital | (3.51 M) | ||||
| Net Asset | 21.97 M |
About Avicanna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avicanna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avicanna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avicanna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Avicanna Stock
Avicanna financial ratios help investors to determine whether Avicanna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avicanna with respect to the benefits of owning Avicanna security.